Top Markets
#1 Wiki Cat Wiki Cat +38.93%
#2 Siren Siren +35.55%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.15%
#4 Velvet Velvet +20.16%
#5 aPriori aPriori +19.57%
#6 Ribbita by Virtuals Ribbita by Virtuals +17.71%
#7 KUB Coin KUB Coin +17.43%
#8 PulseChain PulseChain +17.12%
#9 The Grays Currency The Grays Currency +14.52%
#10 Janction Janction +14.41%
Coin of the day
Wiki Cat Wiki Cat
Settings
Language
ENGLISH
Currency
USD
Theme
Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD
Rank in Stocks #30914
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Share Price
$0.343985
Market Cap
$15.40M
Change (1 day)
3.94%
Change (1 year)
-25.19%
Country
BE
Trade Celyad Oncology S.A. (CYAD)

Category

Healthcare
Number of shares outstanding for Celyad Oncology S.A. (CYAD)
Number of shares outstanding as of August 2026: 0
According to Celyad Oncology S.A. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Celyad Oncology S.A. (CYAD) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0.00 -
BE